Sema4 Signal® Hereditary Cancer
Testing for additional hereditary cancer genes may also be recommended to help improve patient outcomes.
Example of high-risk genes for breast or gynecologic cancers4-13
Family History Questionnaire
Designed to help your patients assess their risk of hereditary cancer. For more information on how to implement this questionnaire within your practice, kindly fill out the contact form at the bottom of this page and someone from our team will be happy to help.
Pre-test educational video
If you believe that a hereditary cancer test is right for your patient, then ask your patient to watch this informational video to learn more about the testing process.
Want to get involved?
The convenient kit below includes the Patient Information Card, social media posts, and email templates customizable for your practice so patients can:
- Understand the importance of knowing their hereditary cancer risk
- Learn how your practice can help support their care
- Take steps to understand if hereditary cancer testing may be appropriate for them
How to choose the right kit
to fit your needs
If you would like to use GeneScreen (GS), a genetic counseling service that will be available to your patients after they complete their Hereditary Cancer Family History Questionnaire. If you already have in-house genetic counseling, please download the Non-GS kit instead.
*MSH3 is available as an add-on gene to any of the Sema4 Signal Hereditary Cancer panels.
1. Lindsay Dohany, et al. Hereditary cancer risk assessment using a chatbot in women presenting to obstetrics and gynecology practices across the U.S. [abstract]. In: Proceedings of the 2019 San Antonio Breast Cancer Symposium; 2019 Dec 10-14; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2020;80(4 Suppl):Abstract nr P6-08-39; 2. Frezzo, T., et al. The genetic family history as a risk assessment tool in internal medicine. Genet Med 5, 84–91 (2003); 3. DeFrancesco MS, et al. Hereditary Cancer Risk Assessment and Genetic Testing in the Community-Practice Setting. Obstet Gynecol. 2018 Nov;132(5):1121-1129; 4. Petrucelli N, Daly MB, Pal T. BRCA1- and BRCA2-Associated Hereditary Breast and Ovarian Cancer. 1998 Sep 4 [Updated 2016 Dec 15]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1247/; 5. Bonadona V, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011 Jun 8;305(22):2304-10; 6. Ryan NAJ, Morris J, Green K, et al. Association of Mismatch Repair Mutation With Age at Cancer Onset in Lynch Syndrome: Implications for Stratified Surveillance Strategies. JAMA Oncol. 2017;3(12):1702–1706; 7. Schon K, Tischkowitz M. Clinical implications of germline mutations in breast cancer: TP53. Breast Cancer Res Treat. 2018;167(2):417-423; 8. Tan MH, et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res. 2012;18(2):400-407; 9. Antoniou AC, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371(6):497-506; 10. Xin Yang, PhD, et al. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families. Journal of Clinical Oncology 38, no. 7 (March 01, 2020) 674-685; 11. Giardiello FM, et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology. 2000 Dec;119(6):1447-53; 12. Hearle N, et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res. 2006 May 15;12(10):3209-15; 13. Kaurah P, et al. Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. JAMA. 2007 Jun 6;297(21):2360-72.